BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06794008 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus
Inflammatory Myopathy
Systemic Sclerosis (SSc)
ANCA-associated Vasculitis
IgG4-Related Diseases
Antiphospholipid Syndrome
Acquired Thrombotic Thrombocytopenic Purpura
Behcet Disease
Sjogren Syndrome

Interventions

DRUG: BCMA-CD19 CAR-T therapy

Sponsor

Peking University People's Hospital